Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

<p><strong>Background:</strong> The effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD).</p> <p><strong>Methods:</...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Herrington, W, Wanner, C, Green, JB
अन्य लेखक: The EMPA-KIDNEY Collaborative Group
स्वरूप: Journal article
भाषा:English
प्रकाशित: Oxford University Press 2022